Nasdaq-listed drugmaker plans up to $800M raise to buy RAIN tokens

Nasdaq-listed biopharmaceutical company Enlivex plans to raise up to $800 million to buy RAIN tokens and has proposed a measure that could significantly dilute shareholder stakes, according to CryptoSlate. The financing plan includes $400 million in investment and an additional $400 million option, with most of the proceeds earmarked for RAIN purchases and up to 5% allocated to drug development. If approved, the company’s outstanding share count could increase by as much as 951% from current levels. As of July 27, local time, Enlivex planned to hold a shareholder meeting within 60 days to seek approval. The media outlet said the plan was closer to a